Archive · 2 Jun 2025
Sun Pharma Plans Expansion Through Acquisitions and Investments
Sun Pharma, a medicine maker, plans to grow its business, especially in areas like cancer, skin, and eye treatments.
They have a lot of money saved up and are looking to buy other companies to help them.
They will spend money to launch two new products in the US.
The company will also invest more in research to test new medicines.
Although sales went up recently, profits went down, but the company expects good growth in the coming year by focusing on key areas and managing costs.
Sun Pharma aims to expand its specialty portfolio through acquisitions in oncology, dermatology, and ophthalmology.
The company has around $3 billion in cash reserves for potential deals.
Sun Pharma plans to spend $100 million in FY26 on the US launch of new specialty products.
R&D investment will increase to 6-8% of sales.
The company anticipates revenue growth in the mid to high single digits for FY26.
- Who
- Sun Pharmaceutical Industries
- What
- Plans to expand specialty portfolio through acquisitions, increased R&D investment and US launches
- When
- Ongoing
- Where
- N/A
- Why
- To grow its business
- Company
- Sun Pharmaceutical Industries
- Cash Reserves
- $3 billion
- R&D Investment
- 6-8% of sales
- FY26 Revenue Growth
- Mid to high single digits
- Q4FY25 Revenue
- ₹12,958.8 crore (up 8.1% YoY)
- Q4FY25 Net Profit
- ₹2,153.9 crore (down 19%)
- FY26 US Launch Spend
- $100 million
